Research Interests
biotechnology
,
cancer/oncogenesis
,
cell growth, differentiation,d
,
drugs/therapeutic agents pharm
,
engineering/bioengineering
,
hormones/cytokines/signalling
,
molecular biology/molecular me
,
structural biology
Recent Publications
Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AKMG, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Debinski W, et al.
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A.
2010;
107(46):20021-6.
Beauchamp AS, Gibo DM, Wykosky J, Debinski W.
Elucidation of the release and function of monomeric ephrina1 in glioblastoma multiforme [abstract]. Neuro Oncol.
2010;
12(Suppl 4):22.
Pandya H, Gibo D, Debinski W.
Development of multiple-specificity vectors for targeted delivery to intracellular compartments of GBM cells [abstract]. Neuro Oncol.
2010;
12(Suppl 4):89.
Lema Tome CM, Wykosky J, Palma E, Debinski W.
Functional and structural characterization of the high-affinity EphA2-binding site of ephrinA1 [abstract]. Neuro Oncol.
2010;
12(Suppl 4):92.
Nguyen V, Murphy LT, Beauchamp AS, Hollingsworth CK, Debinski W, Mintz A.
Combinatorial targeting of EphA2 and IL-13Ralpha2 GBM-restricted biomarkers [abstract]. Neuro Oncol.
2010;
12(Suppl 4):97.
Debinski W, Garg S, Gibo DM, Kridel S, Pandya H.
Isolation and characterization of interleukin 13 receptor alpha2-specific heptapeptides [abstract]. Neuro Oncol.
2009;
11(6):898.
Debinski W, Dickinson P, Gibo DM.
Novel monoclonal antibody 13R2.C3 against iinterleukin [sic] 13 receptor alpha-2 reveals a specific and more widespread expression of the receptor in various brain tumors [abstract]. Neuro Oncol.
2009;
11(6):963.
Wykosky J, Palma E, Gibo D, Ringler S, Turner C, Debinski W.
Metalloprotease cleavage of ephrinA1 releases a functional, soluble, monomeric ligand for the Epha2 receptor [abstract]. Neuro Oncol.
2008;
10(5):774.
Shaw EG, Debinski W, Robbins ME.
Central nervous system tumors: overview. In: Gunderson LL, Tepper JE, eds. Clinical radiation oncology. 2nd ed.
Philadelphia: Elsevier Churchill Livingstone;
2007:
459-492.
Schwartzbaum JA, Ahlbom A, Lonn S, Malmer B, Wigertz A, Auvinen A, Brookes AJ, Christensen HC, Henriksson R, Debinski W, et al.
An international case-control study of interleukin-4R alpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev.
2007;
16(11):2448-2454.
Candolfi M, Xiong W, Muhammad A, Puntel M, Liu C, Kroeger K, Mondkar S, Rodriguez R, Debinski W, Lowenstein P, et al.
Non-leaky, inducible adenoviral-mediated delivery of a mutated form of IL-13 (IL13.E13.K) fused to pseudomonas exotoxin induces regression of intracranial human glioblastoma xenografts [abstract]. Neuro Oncol.
2007;
9(4):493.
Debinski W, Brown W, Gibo D.
FRA-1 transactivates JunB in response to oncogenic activation or stress in GBM cells [abstract]. Neuro Oncol.
2007;
9(4):471.
Debinski W, Gibo D, Wykosky J, Stanton C, Rossmeisl J, Robertson J.
Canine gliomas over-express IL-13Ralpha2, EphA2, and Fra-1 in common with human high-grade astrocytomas [abstract]. Neuro Oncol.
2007;
9(4):535-536.
Liu T, Cai J, Gibo D, Debinski W.
Re-oxygenation of hypoxic glioblastoma multiforme cells potentiates killing effect of interleukin 13-based cytotoxins through re-establishment and further up-regulation of IL13 receptor alpha2 [abstract]. Neuro Oncol.
2007;
9(4):494.
Palma E, Wykosky J, Debinski W.
Structural requirements of ephrinA1 for the effective targeting of EphA2 receptors in gliomas [abstract]. Neuro Oncol.
2007;
9(4):495.
Voelzke WR, Graves JT, Hemphill MB, Gibo DM, Debinski W, Petty WJ, Lesser G.
Pre-clinical evaluation of erlotinib and 13-cis-retinoic acid for the treatment of malignant gliomas [abstract]. Neuro Oncol.
2007;
9(4):492.
Wykosky J, Gibo D, Debinski W.
A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor-expressing tumor cells [abstract]. Neuro Oncol.
2007;
9(4):494.
Wykosky J, Gibo D, Stanton C, Debinski W.
IL-13R alpha2, EphA2, and Fra-1 as molecular denominators of high-grade astrocytomas [abstract]. Neuro Oncol.
2007;
9(4):546.
Debinski W, Gibo D.
Fra-1 regulates and pairs with junB and undergoes phosphorylation in response to oncogenic signaling and irradiation [abstract]. Neuro Oncol.
2006;
8(4):484.
Liu T, Cai J, Gibo D, Debinski W.
Variant IL-13-directed diphtheria toxin fusion recombinant cytotoxin for the treatment of malignant gliomas [abstract]. Neuro Oncol.
2006;
8(4):429.
Wykosky J, Debinski W.
Ephrin A1 is a soluble, monomeric tumor-suppressing protein [abstract]. Neuro Oncol.
2006;
8(4):403-404.
Wykosky J, Debinski W.
Ephrin-A1 is a tumor-suppressing factor in GBM through the activation and downregulation of the EphA2 oncoprotein [abstract]. Neuro Oncol.
2006;
8(4):404.
All Publications
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.